RT Journal Article SR Electronic T1 Phenotypic and functional characterisation of circulating cytomegalovirus-specific T cells in healthy virus carriers and lung transplant candidates JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.04.21256785 DO 10.1101/2021.06.04.21256785 A1 Mohammed Altaf A1 Md Azhar Irfan A1 Nazneen Naheed A1 NM Aleemuddin YR 2021 UL http://medrxiv.org/content/early/2021/06/04/2021.06.04.21256785.abstract AB Background Deficiencies in CMV-specific T cell immunity pre-transplant increase patient risk of CMV reactivation and disease post-transplantation. The aim of this study was to investigate and compare CMV-specific cellular immunity in healthy virus carriers and lung transplant candidates pre-transplant to identify key immune mediators associated with functional defects in CMV-specific T cells.Methods A prospective cohort study of 43 adult lung transplant candidates and 14 healthy virus carriers was conducted in Brisbane, Australia. Intracellular cytokine staining and immune phenotyping (by multiparametric flow cytometry) were performed to explore phenotypic and functional characteristics of CMV-specific T cells.Results In this study, 60% of lung transplant candidates were CMV-seropositive pre-transplant. The numbers of CMV-specific T cells in the periphery were comparable between CMV-seropositive lung transplant candidates and healthy virus carriers. Effector molecule (CD107a, IFN-γ, TNF-α, and IL-2) expression on CMV-specific CD8+ and CD4+ T cells was significantly higher in CMV-seropositive lung transplant candidates compared to healthy virus carriers. However, expression of key T cell function mediators (CD11a, CD29, CD49f, and Granzyme B) was significantly higher in CMV-seropositive lung transplant candidates compared to healthy virus carriers. Conversely, expression levels of CD49d, CD103, and Eomes on T cells and CMV-specific T cells were significantly lower in CMV-seropositive lung transplant candidates compared to healthy virus carriers.Conclusions The findings from this study reveal significant phenotypic differences between healthy virus carriers and lung transplant candidates. Assessment of pre-existing CMV-specific T-cell immunity in lung transplant candidates may help to inform and personalise post-transplant clinical management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Australian National Health and Medical Research Council (APP1132519; APP1062074).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective cohort research was performed according to the principles of the Declaration of Helsinki. Ethics approval to undertake the research involving healthy volunteers was obtained from QIMR Berghofer Human Research Ethics Committee. Ethics approval to undertake the research involving lung transplant candidates was obtained from both The Prince Charles Hospital Human Research Ethics Committee and QIMR Berghofer Medical Research Institute Human Research Ethics Committee. Written informed consent was obtained from all participants prior to inclusion in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request to corresponding author by email.